

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2022 - September 30, 2023

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
Neurology	63867	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy (Xenon XPF-008-201)	Dr Naritoku, D	Xenon Pharmaceuticals, Inc.	

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2022 - September 30, 2023

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
OB-GYN	63887	A Phase 3, Randomized, Double- or Observer-Blinded, Placebo-Controlled Trial to EvaluateThe Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Perfusion FSubunit Vaccine in Infants Born to Women Vaccinated During Pregnancy			

South Alabama Medical Science Foundation
 Cash Receipts (For Projects Over \$2,000)
 October 1, 2022 - September 30, 2023

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
Surgery	63879	Use of Nexobrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries (MediWound MW2018-06-21)	Dr Bright, A	Mediwound	6,128.52
(e)7-33810	33810	The CALIBER Study: Randomized Controlled Trial of LINX versus Double-Dose Pump Inhibitor in the Treatment of Gastroesophageal Reflux Disease (TRX_2018_01)	(b)6-33810 (b)7-33810 (b)8-33810 (b)9-33810 (b)10-33810 (b)11-33810 (b)12-33810 (b)13-33810 (b)14-33810 (b)15-33810 (b)16-33810 (b)17-33810 (b)18-33810 (b)19-33810 (b)20-33810 (b)21-33810 (b)22-33810 (b)23-33810 (b)24-33810 (b)25-33810 (b)26-33810 (b)27-33810 (b)28-33810 (b)29-33810 (b)30-33810 (b)31-33810 (b)32-33810 (b)33-33810 (b)34-33810 (b)35-33810 (b)36-33810 (b)37-33810 (b)38-33810 (b)39-33810 (b)40-33810 (b)41-33810 (b)42-33810 (b)43-33810 (b)44-33810 (b)45-33810 (b)46-33810 (b)47-33810 (b)48-33810 (b)49-33810 (b)50-33810 (b)51-33810 (b)52-33810 (b)53-33810 (b)54-33810 (b)55-33810 (b)56-33810 (b)57-33810 (b)58-33810 (b)59-33810 (b)60-33810 (b)61-33810 (b)62-33810 (b)63-33810 (b)64-33810 (b)65-33810 (b)66-33810 (b)67-33810 (b)68-33810 (b)69-33810 (b)70-33810 (b)71-33810 (b)72-33810 (b)73-33810 (b)74-33810 (b)75-33810 (b)76-33810 (b)77-33810 (b)78-33810 (b)79-33810 (b)80-33810 (b)81-33810 (b)82-33810 (b)83-33810 (b)84-33810 (b)85-33810 (b)86-33810 (b)87-33810 (b)88-33810 (b)89-33810 (b)90-33810 (b)91-33810 (b)92-33810 (b)93-33810 (b)94-33810 (b)95-33810 (b)96-33810 (b)97-33810 (b)98-33810 (b)99-33810 (b)100-33810	Ethicon Endo-Surgery, Inc	1,252.00

South Alabama Medical Science Foundation
 Cash Receipts (For Projects Over \$2,000)
 October 1, 2022 - September 30, 2023

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
	62648	Royalty On Sales of Antibody Products	Dr Scammell, J	QED Bioscience	3,457.60
				Total Other Research	<u>3,457.60</u>
				Total	<u><u>325,252.25</u></u>